Already struggling to make headway with its recently launched Alzheimer's drug, Biogen suffered a major late-stage pipeline setback after its tofersen drug for amyotrophic lateral sclerosis (ALS ...

Biogen will have to make the case for its amyotrophic lateral sclerosis (ALS) therapy tofersen to an FDA advisory committee in March before it gets a decision on approval. The announcement in the ...

Raziel Green, 52, an active runner and mother of two, was diagnosed with a rare form of ALS in 2017. Since starting a ...

QALSODY targets the root cause of SOD1-ALS, an ultra-rare and uniformly fatal neurodegenerative disease marked by motor neuron loss in the brain and spinal cord 1 Biogen's second rare disease ...

QALSODY is the first therapy designed to address the underlying genetic cause of SOD1-ALS2, a rapidly progressive and uniformly fatal condition that impacts motor function, speech, and respiratory ...

QALSODY targets the root cause of SOD1-ALS, an ultra-rare and uniformly fatal neurodegenerative disease marked by motor neuron loss in the brain and spinal cord 1 Biogen's second rare disease therapy ...